Group 1 - The event "Inheriting Good Family Traditions and Good Family Values" organized by Baiyunshan Xiaochaihu celebrated its 8th anniversary, combining traditional Chinese medicine culture with family values [4][12] - The event took place at the Lingshou City Cultural Square in Jinan, featuring various traditional elements and modern vitality, attracting many local residents [4][16] - The event included family story-sharing sessions, where families shared their unique family values, emphasizing the importance of moral education and daily practice [5][18] Group 2 - Interactive segments such as audience Q&A and dialect games were included, allowing participants to engage and learn about traditional Chinese medicine in a fun atmosphere [9][11] - The event highlighted Baiyunshan Xiaochaihu's commitment to social responsibility through various initiatives, including pandemic donations and cultural inheritance [12][18] - The leaders' speeches during the event called for families to work together to promote good family values and spread positive social energy [16][18]

Core Points - The event "Inheriting Good Ancient Recipes, Inheriting Good Family Traditions" by Baiyunshan Xiaochaihu marks its 8th anniversary and aims to promote positive family values in Shandong [1][2] - The event was live-streamed on social media platforms, achieving over 1.14 million views [2] - Baiyunshan Xiaochaihu has been actively involved in social responsibility initiatives, including donations exceeding 10 million yuan for various causes [7] Group 1 - The event was held in Jinan, Shandong, and is part of a broader initiative to spread love and positive energy through family values [1][2] - Baiyunshan Xiaochaihu has organized this event across 12 provinces over the past eight years, sharing over 200 stories of good family traditions [6][15] - The event featured participation from various local leaders and organizations, highlighting community collaboration [6][21] Group 2 - Baiyunshan Xiaochaihu announced a new initiative called "One More Penny of Care," where a portion of sales will be donated to public welfare projects [16] - The company received a gold award at the 50th Geneva International Exhibition for its innovative Xiaochaihu granules, showcasing its commitment to modernizing traditional medicine [15] - The upgraded national standard for Xiaochaihu granules has been included in the 2025 edition of the Chinese Pharmacopoeia, reflecting industry recognition [15] Group 3 - The event included performances and cultural displays, emphasizing the rich cultural heritage of Shandong [24][27] - Families sharing their good family traditions were recognized, reinforcing the importance of family values in society [20][30] - Baiyunshan Xiaochaihu plans to continue its "Finding Good Family Traditions" initiative to enrich cultural life and promote social virtues [30]

Core Viewpoint - A recent network meta-analysis published in a core journal indicates that Baiyunshan Gushen Dingchuan Wan shows superior efficacy in improving clinical effectiveness and forced vital capacity (FVC) for treating stable chronic obstructive pulmonary disease (COPD) [2][3][9]. Group 1: Research Findings - The study reviewed randomized controlled trials of oral traditional Chinese medicine for stable COPD treatment, utilizing a network meta-analysis approach [6][7]. - Results demonstrated that five types of oral traditional Chinese medicines significantly improved treatment outcomes with a high safety profile and minimal adverse reactions [8][9]. - Among the evaluated medicines, Gushen Dingchuan Wan exhibited the best performance in enhancing clinical effectiveness and FVC [9]. Group 2: Treatment Mechanism - Gushen Dingchuan Wan is formulated based on principles of warming the kidneys and lungs, and strengthening the spleen to alleviate symptoms in COPD patients with kidney and lung qi deficiency [10][13]. - The medicine aims to improve lung function and promote respiratory muscle recovery, thereby enhancing patient vitality and quality of life [11][14]. Group 3: Clinical Guidelines and Recommendations - Gushen Dingchuan Wan is included in several authoritative guidelines and consensus recommendations for COPD treatment, such as the "Clinical Application Guidelines for Integrated Traditional and Western Medicine in COPD (2024)" [16][17]. - Its inclusion in these guidelines supports its further application and promotion in the treatment of related diseases [20].

Core Viewpoint - The 2025 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2025 China will be held on July 4-5, 2025, focusing on significant research findings from the ASCO annual meeting and enhancing the influence of Chinese scholars in the international arena [2]. Group 1: Clinical Research Findings - The IV phase clinical study led by Professor Liu Zhigang on "Baiyunshan Nasopharyngeal Detox Granules" demonstrated significant improvements in severe nasal secretion symptoms and reduced the incidence of severe oral mucositis in nasopharyngeal cancer patients undergoing radiotherapy, indicating a promising innovative treatment option [2]. - The study also reported improvements in symptoms such as throat pain and dryness, showcasing good safety profiles for the treatment [2]. Group 2: Background and Development - Radiotherapy remains the primary curative method for nasopharyngeal cancer, with approximately 90% of patients experiencing adverse reactions like radiation-induced oral mucositis, which severely impacts treatment outcomes and quality of life [3]. - Baiyunshan and Huang Zhong Medicine have invested in clinical research since 2022 to address radiation-induced damage in the nasopharyngeal area, with the project supported by prominent experts in the field [3][4]. - Baiyunshan Nasopharyngeal Detox Granules, developed in collaboration with Sun Yat-sen University Cancer Center and Guangzhou Pharmaceutical Group, is clinically used for chronic inflammation and increased secretion symptoms post-radiotherapy [4].

Group 1 - The Artemisinin concept index increased by 0.65%, ranking 10th among concept sectors, with four stocks rising, including Haizheng Pharmaceutical which hit the daily limit, and Zhejiang Medicine, Huaren Shuanghe, and Baiyunshan also showing gains of 0.79%, 0.69%, and 0.08% respectively [1] - The leading decliners in the sector included Rundu Co., New Harmony, and Kunming Pharmaceutical, which fell by 1.41%, 1.36%, and 1.17% respectively [1] - The net inflow of main funds into the Artemisinin concept sector was 95 million yuan, with Haizheng Pharmaceutical receiving the highest net inflow of 105 million yuan, followed by Zhejiang Medicine, New Harmony, and Baihua Pharmaceutical with net inflows of 25.71 million yuan, 9.91 million yuan, and 2.14 million yuan respectively [2][3] Group 2 - In terms of fund inflow ratios, Haizheng Pharmaceutical, Zhejiang Medicine, and Baihua Pharmaceutical had the highest net inflow rates of 9.03%, 5.48%, and 2.27% respectively [3] - The trading performance of key stocks in the Artemisinin concept included Haizheng Pharmaceutical with a daily increase of 10.02% and a turnover rate of 9.22%, while Zhejiang Medicine rose by 0.79% with a turnover rate of 3.19% [3][4] - Other stocks such as New Harmony and Baihua Pharmaceutical experienced declines of 1.36% and 0.41% respectively, with turnover rates of 1.04% and 3.34% [3][4]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/ ...

Group 1 - The Jilin Provincial Health and Family Planning Commission and the Jilin Provincial Finance Department have implemented a cost subsidy system for maternity leave, providing a subsidy of 2000 yuan per female employee who gives birth, effective from January 1, 2025 [1] - More companies, including Sanqi Interactive Entertainment, Jingpai Company, Xiaopeng Motors, Ctrip, and Kuaishou, are joining the initiative to encourage childbirth, contributing to a pro-natalist atmosphere in society [1] - The establishment of more cost-sharing mechanisms for maternity leave is deemed important, especially for companies facing operational pressures [1] Group 2 - Lucky Coffee has surpassed 6000 stores nationwide, covering over 300 cities across 30 provincial-level administrative regions, and is expanding its presence in high-tier cities [2] - The Chinese fresh coffee market is experiencing rapid growth, with a projected compound annual growth rate of 19.8% from 2023 to 2028, making it the fastest-growing segment in the ready-to-drink beverage market [2] - The competitive landscape in the coffee market remains intense, raising questions about Lucky Coffee's ability to sustain its growth and scale [2] Group 3 - Guangzhou Pharmaceutical Group's Wanglaoji has signed a partnership with Japan's Futaba Industry to enhance its market presence in Japan, focusing on channel sharing and brand promotion [3] - Since entering the Japanese market in 2020, Wanglaoji has successfully established itself in major retail and convenience store channels [3] - The collaboration with Futaba Industry is expected to boost Wanglaoji's overseas market share and brand value, with future market performance being closely monitored [3] Group 4 - Alibaba's chairman, Cai Chongxin, has made a significant impact during the NBA draft by selecting five rookies, setting a record for the most players picked by a single team in a draft [4] - Cai and his wife control the New York Liberty team in the WNBA, indicating their strong presence in the sports investment sector [4] - Cai emphasizes that sports teach valuable lessons applicable to business, such as discipline and resilience in the face of failure [4]

Core Insights - This year, Guangdong is experiencing a bumper harvest of lychee, with production expected to exceed 2 million tons by 2025 [1] - The Guangdong Lychee (Maoming) Industrial Park, established in 2022, is equipped with the most advanced lychee juice production line in China, with an annual planned capacity of 9 million boxes [1] - The company aims to alleviate the issue of increased production without increased income through deep processing of lychee [1] Group 1 - The lychee season is in full swing, with farmers actively harvesting and transporting fresh lychee to the processing facility [1] - The company plans to process 700,000 pounds of fresh lychee by early July this year [1] - The "order agriculture production and sales connection model" developed by the company has led to significant daily deliveries of fresh lychee to the juice factory [1] Group 2 - The company has developed various beverages and derivative foods using lychee, including juice, electrolyte water, and bubble water, as well as products like lychee turtle jelly and bird's nest [2] - Over 200 tons of lychee pulp have been sold, corresponding to the processing of 500 tons of fresh lychee [2] - A comprehensive lychee industry chain focused on deep processing is efficiently operating in Guangdong, contributing to the province's billion-dollar lychee industry [2]

Group 1 - The event held in Osaka on June 26 was a significant part of the Guangdong activities during the 2025 Osaka World Expo, attracting over 100 participants from Japanese business circles and well-known companies [1] - Guangzhou is highlighted as a vital economic hub with a rich history of over 2,000 years of openness, serving as a key window for China to engage with the world [2] - Over the past decade, Guangzhou has utilized more than $130 billion in foreign investment, with foreign enterprises contributing 20% of the city's service industry revenue, 30% of its import and export value, and 40% of its industrial added value [2] Group 2 - The event aimed to deepen exchanges between Chinese and Japanese business communities, with expectations to enhance understanding of Guangzhou's economic and investment dynamics [3] - The Osaka World Trade Center Association is facilitating cooperation and investment opportunities for Guangzhou enterprises in Japan, particularly through the promotion of Japanese century-old companies [3] - The collaboration between Guangzhou's pharmaceutical companies and Japanese firms is emphasized, with significant agreements reached during the event, marking a breakthrough for Guangzhou's health products in the Japanese market [4]

廣州白雲山醫藥集團股份有限公司 董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 關連交易進展公告 向白雲山生物增資 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）日期為2025年5月28日之公告（「該公告」）,內容 有關向白雲山生物增資之關連交易。除另有界定外，本公告所用詞彙與該公告所界定者具有相同涵 義。 董事會欣然宣佈於2025年6月30日，本公司與廣藥創投基金、廣州老字號基金、廣藥產投基金、國資 併購基金、拜迪生物及白雲山生物訂立了增資協議，增資協議於同日正式生效。增資協議的主要條 款並無任何變更。增資協議的主要條款及本次增資詳情載於該公告。 本次增資完成後，本公司於白雲山生物的直接及間接持股比例維持不變，仍為50.00%。白雲山生物 仍為本公司之附屬公司，其財務業績繼續納入本公司之合併報表。 中國廣州，2025年6月30日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執 ...